Navigation Links
Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
Date:12/2/2008

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Biomarkers Inc, a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the formation of a Scientific Advisory Board consisting of internationally renowned scientists and physicians at the forefront of biomarker and clinical research. The Scientific Advisory Board includes:

-- Daniel W. Chan, Ph.D., Director of the Center for Biomarker Discovery and Director, Clinical Chemistry Division, at Johns Hopkins Medical Institution. In addition to his responsibilities of heading the hospital clinical chemistry laboratory, Dr. Chan conducts cutting edge research using state of the art proteomic techniques for biomarker discovery. His overall goals are the identification and characterization of novel biomarkers for the diagnosis and treatment of cancer.

-- Johann de Bono, M.D., Ph.D., Senior Lecturer at The Institute for Cancer Research, Royal Marsden Hospital. Dr. de Bono is leader of the Prostate Cancer Team and directs the clinical drug development Phase I trials program at Royal Marsden Hospital, with a particular interest in pharmacokinetic - pharmacodynamic evaluation of targeted therapeutics.

-- John Heymach, M.D., Ph.D., Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. The goal of Dr. Heymach's clinical, translational and laboratory research is to advance the development of targeted agents, particularly angiogenesis inhibitors for non-small lung cancer, by incorporating biomarkers into clinical trials to improve patient outcomes.

-- Peter Maimonis, Ph.D. Vice President of Biological Research, Decision Biomarkers, Waltham, MA. Dr. Maimonis has been involved in the discovery and validation of tumor biomarkers for over 20 years. His research has focused on diagnostic markers for breast and colorectal cancer. He has also developed assays for many of these biomarkers, taking a number of them through FDA approval.

-- Larry Oliver, Ph.D., Scientific Director of Mayo Clinical Trial Services and Director of the Metals Laboratory in the Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, MN. Dr. Oliver's research includes performance definitions of surrogate biomarkers of efficacy, antibody-antigen binding characterization, and clinical and analytical validation of biomarkers of safety.

"We are extremely pleased to have recruited such an outstanding group of visionary thought leaders to our SAB", said Roger Dowd, President and CEO of DBI. "We look forward to their expert guidance to enable us to realize the full potential of our multiplex immunoassay technology for drug development". About Decision Biomarkers Inc Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving productivity improvement in the pharmaceutical and diagnostic industries by supplying automated, multiplex protein biomarker systems that can be used by virtually anyone, anywhere and in real time.

www.decisionbiomarkers.com


'/>"/>
SOURCE Decision Biomarkers Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
2. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
5. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
8. Scientists Using Social Media to Inform Lab Purchasing Decisions
9. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
10. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):